Gotham Asset Management’s Travere Therapeutics TVTX Stock Holding History

Gotham Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$843K	Sell	28,377 -27,607	-49%	-$825K	﹤0.01%	1361
2025 Q4	$2.14M	Buy	55,984 +28,241	+102%	+$918K	0.01%	1021
2025 Q3	$663K	Buy	+27,743	New	+$522K	﹤0.01%	1321
2015 Q4	–	Sell	-25,289	Closed	-$512K	–	1017
2015 Q3	$512K	Buy	25,289 +8,307	+49%	+$246K	0.01%	723
2015 Q2	$563K	Buy	+16,982	New	+$465K	﹤0.01%	717

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gotham Asset Management's TVTX Position: Q1 2026 in Review

Gotham Asset Management reduced its Travere Therapeutics (TVTX) stake by 49% in Q1 2026, selling an estimated $825K and leaving 28,377 shares worth $843K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Gotham Asset Management first reported a position in TVTX in Q2 2015 and has held it in 5 quarters since. The position peaked at $2.14M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Gotham Asset Management held 28,377 shares of Travere Therapeutics worth $843K as of Q1 2026.
Gotham Asset Management sold 27,607 Travere Therapeutics shares in Q1 2026, an estimated $825K.
Travere Therapeutics made up ﹤0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1361 holding.
Gotham Asset Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 5 quarters since.
Gotham Asset Management's Travere Therapeutics position peaked at $2.14M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.